What AI says about Ultragenyx
AI summary
Ultragenyx is a biopharmaceutical company focused on developing and commercializing medicines for rare and ultra-rare diseases.
AI named Ultragenyx from November 2025 to September 2026.
Ultragenyx in AI’s own words
Question: What are the latest affordable advancements in biopharma for treating rare diseases?
Google AI ModeSep 2, 2026
Major biotechnology portfolios (such as those managed by BioMarin Rare Disease Biotechnology and Ultragenyx ) are scaling up production efficiency.
Question: What are the latest affordable advancements in biopharma for treating rare diseases?
ChatGPT SearchAug 29, 2026
Ultragenyx Pharmaceutical received approval for a gene therapy targeting glycogen storage disease type Ia
Questions and answers
Excerpts where Ultragenyx appeared in the AI's answer
Google AI ModeSep 2, 2026, Google AI Mode Major biotechnology portfolios (such as those managed by BioMarin Rare Disease Biotechnology and Ultragenyx ) are scaling up production efficiency.
ChatGPT SearchAug 29, 2026, ChatGPT Search Ultragenyx Pharmaceutical received approval for a gene therapy targeting glycogen storage disease type Ia
Competitors
AI named Ultragenyx most often alongside Alnylam Pharmaceuticals, Amvuttra, and Anthropic.
Sources AI cites
None of these answers cited ultragenyx.com. AI leaned on fda.gov, reuters.com, and wewillcure.com.
ultragenyx.com 0%Other sites 100%
